Amniotics AB

AMNI

SE0015961016

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 15/07/2024 pm IST			5-day change	1st Jan Change
0.0054 ^SEK	0.00%		0.00%	-40.00%

20/05	Magle Chemoswed Holding AB (OM:MAGLE) cancelled the acquisition of 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other.	CI
22/03	Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	CI

Amniotics Q4 2022 - Our Comments

January 23, 2023 at 11:00 pm IST

Redeye comments on the events of the fourth quarter, including progress with the main candidate PulmoStem and the rights issue.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Latest news about Amniotics AB

Magle Chemoswed Holding AB (OM:MAGLE) cancelled the acquisition of 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other.	20/05	CI
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	22/03	CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
Amniotics Secures Orphan Designation for Lung Injury Therapy from European Commission	14/12	MT
Amniotics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/11	CI
Amniotics AB Gets Renewed GMP Certification for Medicinal Products Manufacturing Site	23/11	MT
European Medicines Agency Panel Backs Amniotics AB’s PulmoStem for Orphan Designation	20/11	MT
Amniotics AB Receives Positive Opinion on Orphan Designation for PulmoStem from the European Medicines Agency for the Treatment of Primary Graft Dysfunction Following Lung Transplantation	20/11	CI
Amniotics AB Receives Final Clinical Study Report for the Phase Ib Clinical Trial	13/23/13	CI
Certain Ordinary Shares of Amniotics AB are subject to a Lock-Up Agreement Ending on 9-SEP-2023.	09/23/09	CI
Amniotics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/23/31	CI
Amniotics AB Announces Delay in Publication of Earnings Result for the Second Quarter of 2023	17/23/17	CI
Amniotics AB Announces Positive Interim Results with CogniStem	05/23/05	CI
Amniotics AB Receives Positive Topline Results from Clinical Phase Ib Study with PulmoStem	25/23/25	CI
Amniotics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
Amniotics AB Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Swedish Biotech Amniotics Namese New CFO	20/23/20	MT
Amniotics Announces CFO Changes	20/23/20	CI
Amniotics AB Receives Positive Information About Safety Data for PulmoStem in Clinical Study	02/23/02	CI
Amniotics AB Completes Phase Ib Study of PulmoStem	16/23/16	CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 30, 2022	19/23/19	CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 30, 2022	19/23/19	CI
Amniotics AB Receives Positive Safety Data from PulmoStem™ Clinical Study	19/22/19	CI
Amniotics-led Consortium Wins EU Grant for Anti-Cancer Cells Program	14/22/14	MT

Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AMNIOTICS AB	-40.00%	1.39M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.94%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research

Amniotics AB

Equities

AMNI

SE0015961016

Biotechnology & Medical Research

Amniotics Q4 2022 - Our Comments

Latest news about Amniotics AB

Chart Amniotics AB

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research